• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Novartis' Sandoz, following Pfizer's lead, launches 2nd carcinogen-related drug...

cafead

Administrator
Staff member
  • cafead   Mar 23, 2022 at 11:02: PM
via Right on the heels of Pfizer’s Accuretic recall, nitrosamine impurities have forced another major drugmaker to pull certain meds from U.S. shelves.

Novartis’ Sandoz is recalling 13 lots of oral orphenadrine citrate 100-mg extended-release tablets after testing flagged unacceptable levels of a potential carcinogen dubbed NMOA, or Nitroso-Orphenadrine.

article source
 

<